• 한국염색가공학회:학술대회논문집
• /
• 한국염색가공학회 2010년도 제3회 국제학회
• /
• pp.191-192
• /
• 2010

• 한국염색가공학회:학술대회논문집
• /
• 한국염색가공학회 2010년도 제3회 국제학회
• /
• pp.43-44
• /
• 2010

• Journal of Microbiology and Biotechnology
• /
• 제30권8호
• /
• pp.1109-1115
• /
• 2020

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading globally, and the WHO has declared this outbreak a pandemic. Vaccines are an effective way to prevent the rapid spread of COVID-19. Furthermore, the immune response against SARS-CoV-2 infection needs to be understood for the development of an efficient and safe vaccine. Here, we review the current understanding of vaccine targets and the status of vaccine development for COVID-19. We also describe host immune responses to highly pathogenic human coronaviruses in terms of innate and adaptive immunities.

• Journal of Microbiology and Biotechnology
• /
• 제30권12호
• /
• pp.1843-1853
• /
• 2020

COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.

• Journal of Microbiology and Biotechnology
• /
• 제30권3호
• /
• pp.313-324
• /
• 2020

Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.

• 한국위성정보통신학회논문지
• /
• 제4권2호
• /
• pp.1-4
• /
• 2009

본 논문에서는 우주기술과 정보기술 융합이 단순한 화두가 아니라 우리나라 신성장동력 엔진의 키워드로 자리매김 할 수 있도록 ST-IT 융합기술이 무엇이고, 우리나라의 ST 및 IT 기술현황을 소개한다. 향후 ST-IT 융합기술의 발달에 따라 기술 및 산업 간의 벽이 허물어지고 새로운 가치와 시장이 창출되는 등 역동적인 변화가 예상되기 때문에 향후 ST-IT 융합기술 발전 방향을 제시하고자 한다.

• 한국염색가공학회:학술대회논문집
• /
• 한국염색가공학회 2010년도 제3회 국제학회
• /
• pp.193-193
• /
• 2010

• 한국염색가공학회:학술대회논문집
• /
• 한국염색가공학회 2010년도 제3회 국제학회
• /
• pp.186-186
• /
• 2010

• Journal of Microbiology and Biotechnology
• /
• 제33권8호
• /
• pp.981-991
• /
• 2023

Monkeypox (Mpox) virus, a member of the Poxviridae family, causes a severe illness similar to smallpox, which is characterized by symptoms such as high fever, rash, and pustules. Human-to-human transmission cases have been reported but remained low since the first recorded case of human infection occurred in the Congo in 1970. Recently, Mpox has re-emerged, leading to an alarming surge in infections worldwide since 2022, originating in the United Kingdom. Consequently, the World Health Organization (WHO) officially declared the '2022-23 Mpox outbreak'. Currently, no specific therapy or vaccine is available for Mpox. Therefore, patients infected with Mpox are treated using conventional therapies developed for smallpox. However, the vaccines developed for smallpox have demonstrated only partial efficacy against Mpox, allowing viral transmission among humans. In this review, we discuss the current epidemiology of the ongoing Mpox outbreak and provide an update on the progress made in diagnosis, treatment, and development of vaccines for Mpox.

• Bulletin of the Korean Chemical Society
• /
• 제31권6호
• /
• pp.1757-1760
• /
• 2010